P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program
Joseph L. Pipicella(Ingham Institute), Susan J. Connor(Liverpool Hospital), Graham Radford‐Smith(QIMR Berghofer Medical Research Institute), Kate D. Lynch(Royal Adelaide Hospital), Ian C. Lawrance(The University of Western Australia), G Walker(The University of Queensland), Richard B. Gearry(Waitaki Biosciences (New Zealand)), Jane M. Andrews(Health Net), Simon Ghaly(UNSW Sydney), Wyndham H. Wilson(National Institutes of Health), Jakob Begun(Translational Research Institute), Jack McNamara, Astrid‐Jane Williams, L Brett(Logan Hospital), Michael Schultz
Cited by 0
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k